SCHEMBL17239452

SCHEMBL17239452

CCOC(=O)c1cc(N)n(-c2cccc(OCc3ccccc3)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.53
LIPC P11150 1/20 0.53
ACHE P22303 1/20 0.53
LIPE Q05469 1/20 0.53
KMT2A Q03164 4/20 0.50
MEN1 O00255 2/20 0.50
GAA P10253 1/20 0.50
HSP90AA1 P07900 1/20 0.50
GABRA1 P14867 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA5 P31644 1/20 0.49
GABRA3 P34903 1/20 0.49
GABRA2 P47869 1/20 0.49
TP53 P04637 3/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 2/20 0.47
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835335 0.85 KMT2A (0.65) KMT2AMEN1GAATP53POLB
SCHEMBL17251652 0.85 FAAH (0.48) KMT2AMEN1GAATP53POLB
SCHEMBL1764908 0.81 FAAH (0.59) BCHELIPCACHELIPEGABRA2
SCHEMBL31567108 0.81 CYP1A2 (0.61) BCHELIPCACHELIPEKMT2A
SCHEMBL16517015 0.80 KMT2A (0.50) KMT2AMEN1GAATP53POLB
SCHEMBL4705431 0.77 KMT2A (0.47) KMT2AMEN1GAATP53POLB
SCHEMBL6586118 0.77 MAPT (0.57) KMT2AMEN1GAAPOLBMAPT
SCHEMBL4927623 0.76 MDM2 (0.57) KMT2AMEN1GAAGABRA1GABRG2
SCHEMBL10317229 0.76 PDE4B (0.68) KMT2AMEN1MAPTALDH1A1
SCHEMBL14357214 0.76 ALDH1A1 (0.54) KMT2AMEN1GAATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3140298-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS Pfizer Inc. (US) 2017-03-15 EP disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
WO-2015170218-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2015-11-12 WO disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS TPM3, MUSK, TPM4 BCHE 3273/4885LIPC 4561/4885ACHE 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.